He specializes in financial planning, audit, compliance and ERP implementation, with extensive experience in leading automation and risk management projects
The company has posted net profit) of Rs.18.88 crores for the Financial Year ended March 31, 2024
Hester Biosciences has reported total income of Rs. 88.99 crores during the period ended June 30, 2023
The company has reported total income of Rs. 79.33 crores during the period ended December 31, 2022
The company has reported total income of Rs. 77.60 crores during the period ended September 30, 2022
Hester's initial pet care portfolio will include products ranging from dermatology, grooming, anti-infective, and speciality products
The consideration for the acquisition is US $ 2.25 million
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
CDSCO to fast-track trials and approval for COVID19 vaccine
Subscribe To Our Newsletter & Stay Updated
